Table 1. Baseline patient characteristics.
| Characteristic | mFOLFIRINOX (n=25) | GEMOX (n=19) | P value |
|---|---|---|---|
| Male sex, n (%) | 9 (36.0) | 6 (31.6) | 0.759 |
| Age (y) | |||
| Mean (SD) | 60.8 (9.8) | 62.6 (10.3) | |
| ≥60 y, n (%) | 14 (56.0) | 10 (52.6) | 0.824 |
| ECOG, n (%) | 0.680 | ||
| 0 | 9 (36.0) | 8 (42.1) | |
| 1 | 16 (64.0) | 11 (57.9) | |
| Clinical T stage, n (%) | 0.600 | ||
| T3 | 21 (84.0) | 17 (89.5) | |
| T4 | 4 (16.0) | 2 (10.5) | |
| Disease status, n (%) | 0.272 | ||
| Unresectable locally advanced | 12 (48.0) | 6 (31.6) | |
| Metastatic | 13 (52.0) | 13 (68.4) | |
| Liver | 11 (44.0) | 9 (47.4) | |
| Pancreas | 1 (4.0) | 1 (5.3) | |
| Lung | 1 (4.0) | 0 (0.0) | |
| Peritoneum | 2 (8.0) | 2 (10.5) | |
| Distant lymph node | 4 (16.0) | 2 (10.5) | |
| Median CA19-9 (range, IU/mL) | 69.4 (2.7–5,669.0) | 76.0 (2.9–9,475.0) | 0.429 |
ECOG, Eastern Cooperative Oncology Group.